Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (4): 330-336.DOI: 10.3969/j.issn.1673-8640.2023.04.006
Previous Articles Next Articles
YANG Jielin, WANG Xiaoyuan, LI Haixia
Received:
2021-10-14
Revised:
2023-02-03
Online:
2023-04-28
Published:
2023-06-21
CLC Number:
YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer[J]. Laboratory Medicine, 2023, 38(4): 330-336.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.04.006
基因 名称 | 引物序列(5'~ 3') | 大小/bp |
---|---|---|
TRX | F:CATATGGTGAAGCAGATCGAGAG | 403 |
R:TGTCACGCAGATGGCAACTG | 293 | |
TXNIP | F:GACTTCGGAGTACCTGCGC | 110 |
R:AAGCTCAAAGCCGAACTTGTACTCA | 165 | |
GAPDH | F:TGTGAAGGTCGG TGTGAAC | 220 |
R:CAGATGGTGATGGG CTGCC | 263 |
基因 名称 | 引物序列(5'~ 3') | 大小/bp |
---|---|---|
TRX | F:CATATGGTGAAGCAGATCGAGAG | 403 |
R:TGTCACGCAGATGGCAACTG | 293 | |
TXNIP | F:GACTTCGGAGTACCTGCGC | 110 |
R:AAGCTCAAAGCCGAACTTGTACTCA | 165 | |
GAPDH | F:TGTGAAGGTCGG TGTGAAC | 220 |
R:CAGATGGTGATGGG CTGCC | 263 |
组织 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/ [例(%)] |
---|---|---|---|
癌旁组织 | 116 | 11(9.48) | 94(81.03) |
癌前病变组织 | 116 | 52(44.83) | 72(62.07) |
癌组织 | 116 | 100(86.21) | 36(31.03) |
χ2值 | 12.587 | 3.985 | |
P值 | 0.000 | 0.041 |
组织 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/ [例(%)] |
---|---|---|---|
癌旁组织 | 116 | 11(9.48) | 94(81.03) |
癌前病变组织 | 116 | 52(44.83) | 72(62.07) |
癌组织 | 116 | 100(86.21) | 36(31.03) |
χ2值 | 12.587 | 3.985 | |
P值 | 0.000 | 0.041 |
临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] | 临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] |
---|---|---|---|---|---|---|---|
性别 | 淋巴转移 | ||||||
男性 | 65 | 55(84.62) | 20(30.77) | 有 | 71 | 63(88.73) | 23(32.39) |
女性 | 51 | 45(88.24) | 16(31.37) | 无 | 45 | 31(68.89) | 23(51.11) |
χ2值 | 0.018 | 0.015 | χ2值 | 7.057 | 4.032 | ||
P值 | 0.895 | 0.907 | P值 | 0.008 | 0.045 | ||
年龄 | 临床分期 | ||||||
<60岁 | 44 | 37(84.09) | 12(27.27) | Ⅰ~Ⅱ期 | 65 | 57(87.69) | 21(32.31) |
≥60岁 | 72 | 63(87.50) | 24(33.33) | Ⅲ~Ⅳ期 | 51 | 43(84.31) | 15(29.41) |
χ2值 | 0.018 | 0.075 | χ2值 | 0.068 | 3.635 | ||
P值 | 0.903 | 0.768 | P值 | 0.703 | 0.036 | ||
肿瘤直径 | 浸润深度 | ||||||
>5 cm | 68 | 59(86.76) | 21(30.88) | 浆膜层 | 71 | 57(80.28) | 22(30.99) |
≤5 cm | 48 | 41(85.42) | 15(31.25) | 肌层 | 45 | 43(95.56) | 14(31.11) |
χ2值 | 0.052 | 0.879 | χ2值 | 4.156 | 6.692 | ||
P值 | 0.889 | 0.281 | P值 | 0.021 | 0.035 | ||
组织学分级 | 肿瘤位置 | ||||||
高+中 | 78 | 68(87.18) | 26(33.33) | 结肠 | 83 | 76(91.57) | 25(30.12) |
低 | 38 | 32(84.21) | 10(26.32) | 直肠 | 33 | 24(72.73) | 11(33.33) |
χ2值 | 1.551 | 1.035 | χ2值 | 4.133 | 0.085 | ||
P值 | 0.460 | 0.261 | P值 | 0.041 | 0.804 | ||
临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] | 临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] |
T分期 | M分期 | ||||||
T1~T2期 | 35 | 24(68.57) | 10(28.57) | M0期 | 89 | 77(86.52) | 26(29.21) |
T3~T4期 | 81 | 76(93.83) | 26(32.10) | M1期 | 27 | 23(85.19) | 10(37.04) |
χ2值 | 7.450 | 6.494 | χ2值 | 6.435 | 1.577 | ||
P值 | 0.006 | 0.039 | P值 | 0.012 | 0.209 | ||
N分期 | 癌胚抗原 | ||||||
N0期 | 79 | 71(89.87) | 25(31.65) | ≤5 μg/L | 62 | 55(88.71) | 19(30.65) |
N1期 | 28 | 23(82.14) | 8(28.57) | >5 μg/L | 17 | 13(76.47) | 5(29.41) |
N2期 | 9 | 6(66.67) | 3(33.33) | 未知 | 37 | 32(86.49) | 12(32.43) |
χ2值 | 7.758 | 11.517 | χ2值 | 2.017 | 1.813 | ||
P值 | 0.033 | 0.008 | P值 | 0.047 | 0.066 |
临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] | 临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] |
---|---|---|---|---|---|---|---|
性别 | 淋巴转移 | ||||||
男性 | 65 | 55(84.62) | 20(30.77) | 有 | 71 | 63(88.73) | 23(32.39) |
女性 | 51 | 45(88.24) | 16(31.37) | 无 | 45 | 31(68.89) | 23(51.11) |
χ2值 | 0.018 | 0.015 | χ2值 | 7.057 | 4.032 | ||
P值 | 0.895 | 0.907 | P值 | 0.008 | 0.045 | ||
年龄 | 临床分期 | ||||||
<60岁 | 44 | 37(84.09) | 12(27.27) | Ⅰ~Ⅱ期 | 65 | 57(87.69) | 21(32.31) |
≥60岁 | 72 | 63(87.50) | 24(33.33) | Ⅲ~Ⅳ期 | 51 | 43(84.31) | 15(29.41) |
χ2值 | 0.018 | 0.075 | χ2值 | 0.068 | 3.635 | ||
P值 | 0.903 | 0.768 | P值 | 0.703 | 0.036 | ||
肿瘤直径 | 浸润深度 | ||||||
>5 cm | 68 | 59(86.76) | 21(30.88) | 浆膜层 | 71 | 57(80.28) | 22(30.99) |
≤5 cm | 48 | 41(85.42) | 15(31.25) | 肌层 | 45 | 43(95.56) | 14(31.11) |
χ2值 | 0.052 | 0.879 | χ2值 | 4.156 | 6.692 | ||
P值 | 0.889 | 0.281 | P值 | 0.021 | 0.035 | ||
组织学分级 | 肿瘤位置 | ||||||
高+中 | 78 | 68(87.18) | 26(33.33) | 结肠 | 83 | 76(91.57) | 25(30.12) |
低 | 38 | 32(84.21) | 10(26.32) | 直肠 | 33 | 24(72.73) | 11(33.33) |
χ2值 | 1.551 | 1.035 | χ2值 | 4.133 | 0.085 | ||
P值 | 0.460 | 0.261 | P值 | 0.041 | 0.804 | ||
临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] | 临床病理特征 | 例数 | TRX阳性/ [例(%)] | TXNIP阳性/[例(%)] |
T分期 | M分期 | ||||||
T1~T2期 | 35 | 24(68.57) | 10(28.57) | M0期 | 89 | 77(86.52) | 26(29.21) |
T3~T4期 | 81 | 76(93.83) | 26(32.10) | M1期 | 27 | 23(85.19) | 10(37.04) |
χ2值 | 7.450 | 6.494 | χ2值 | 6.435 | 1.577 | ||
P值 | 0.006 | 0.039 | P值 | 0.012 | 0.209 | ||
N分期 | 癌胚抗原 | ||||||
N0期 | 79 | 71(89.87) | 25(31.65) | ≤5 μg/L | 62 | 55(88.71) | 19(30.65) |
N1期 | 28 | 23(82.14) | 8(28.57) | >5 μg/L | 17 | 13(76.47) | 5(29.41) |
N2期 | 9 | 6(66.67) | 3(33.33) | 未知 | 37 | 32(86.49) | 12(32.43) |
χ2值 | 7.758 | 11.517 | χ2值 | 2.017 | 1.813 | ||
P值 | 0.033 | 0.008 | P值 | 0.047 | 0.066 |
组织 | 例数 | TRX | TXNIP | |||
---|---|---|---|---|---|---|
蛋白 | mRNA | 蛋白 | mRNA | |||
癌组织 | 116 | 2.69±0.43 | 2.47±0.45 | 0.26±0.05 | 0.24±0.13 | |
癌前病变组织 | 116 | 1.95±0.38 | 1.89±0.60 | 0.88±0.35 | 0.91±0.24 | |
癌旁组织 | 116 | 1.47±0.33 | 1.34±0.71 | 1.53±0.60 | 1.46±0.35 | |
F值 | 6.038 | 4.148 | 11.756 | 7.756 | ||
P值 | 0.006 | 0.021 | <0.001 | <0.001 |
组织 | 例数 | TRX | TXNIP | |||
---|---|---|---|---|---|---|
蛋白 | mRNA | 蛋白 | mRNA | |||
癌组织 | 116 | 2.69±0.43 | 2.47±0.45 | 0.26±0.05 | 0.24±0.13 | |
癌前病变组织 | 116 | 1.95±0.38 | 1.89±0.60 | 0.88±0.35 | 0.91±0.24 | |
癌旁组织 | 116 | 1.47±0.33 | 1.34±0.71 | 1.53±0.60 | 1.46±0.35 | |
F值 | 6.038 | 4.148 | 11.756 | 7.756 | ||
P值 | 0.006 | 0.021 | <0.001 | <0.001 |
组织 | 例数 | TRX mRNA 高表达/[例(%)] | TRX蛋白高表达/[例(%)] | TXNIP mRNA 低表达/[例(%)] | TXNIP蛋白低表达/[例(%)] |
---|---|---|---|---|---|
癌旁组织 | 116 | 39(33.62) | 37(31.90) | 46(39.66) | 44(37.93) |
癌前病变组织 | 116 | 69(59.48) | 57(49.14) | 77(66.38) | 65(56.03) |
癌组织 | 116 | 89(76.72) | 94(81.03) | 96(82.76) | 91(78.45) |
χ2值 | 44.455 | 58.054 | 47.080 | 39.103 | |
P值 | 0.000 | 0.000 | 0.000 | 0.000 |
组织 | 例数 | TRX mRNA 高表达/[例(%)] | TRX蛋白高表达/[例(%)] | TXNIP mRNA 低表达/[例(%)] | TXNIP蛋白低表达/[例(%)] |
---|---|---|---|---|---|
癌旁组织 | 116 | 39(33.62) | 37(31.90) | 46(39.66) | 44(37.93) |
癌前病变组织 | 116 | 69(59.48) | 57(49.14) | 77(66.38) | 65(56.03) |
癌组织 | 116 | 89(76.72) | 94(81.03) | 96(82.76) | 91(78.45) |
χ2值 | 44.455 | 58.054 | 47.080 | 39.103 | |
P值 | 0.000 | 0.000 | 0.000 | 0.000 |
模型 | TBA | CVC | P值 | CVC调整 | P值调整 |
---|---|---|---|---|---|
癌组织 | |||||
A2 | 0.565 | 7/10 | 0.001 | 7/10 | 0.001 |
A2A3 | 0.776 | 9/10 | 0.001 | 7/10 | 0.001 |
A2A3A4 | 0.771 | 9/10 | 0.001 | 9/10 | 0.001 |
A1A2A3A4 | 0.785 | 10/10 | 0.001 | 10/10 | 0.001 |
癌前病变组织 | |||||
A1 | 0.451 | 6/10 | 0.990 | 6/10 | 0.990 |
A1A3 | 0.572 | 9/10 | 0.828 | 9/10 | 0.801 |
A1A3A4 | 0.447 | 4/10 | 0.623 | 6/10 | 0.576 |
A1A2A3A4 | 0.483 | 10/10 | 0.828 | 10/10 | 0.588 |
模型 | TBA | CVC | P值 | CVC调整 | P值调整 |
---|---|---|---|---|---|
癌组织 | |||||
A2 | 0.565 | 7/10 | 0.001 | 7/10 | 0.001 |
A2A3 | 0.776 | 9/10 | 0.001 | 7/10 | 0.001 |
A2A3A4 | 0.771 | 9/10 | 0.001 | 9/10 | 0.001 |
A1A2A3A4 | 0.785 | 10/10 | 0.001 | 10/10 | 0.001 |
癌前病变组织 | |||||
A1 | 0.451 | 6/10 | 0.990 | 6/10 | 0.990 |
A1A3 | 0.572 | 9/10 | 0.828 | 9/10 | 0.801 |
A1A3A4 | 0.447 | 4/10 | 0.623 | 6/10 | 0.576 |
A1A2A3A4 | 0.483 | 10/10 | 0.828 | 10/10 | 0.588 |
1. | 政峰, 翟晓璐, 王维健, 等. LRFN4在结直肠癌组织中的表达和临床意义[J]. 中华医学杂志, 2020, 100(22):5. |
2. | 马春艳. 结直肠癌组织中核运转蛋白KPNA2的表达及其与结直肠癌临床病理特征之间的关系[J]. 河北医学, 2020, 26(2):197-201. |
3. | 王雪娇, 史文娟, 张燕, 等. 硫氧还蛋白相互作用蛋白介导的炎症反应及细胞凋亡在心肌梗死中的作用[J]. 中国组织工程研究, 2023, 27(11):1715-1721. |
4. | 杨婕琳, 陈文婷, 高会斌. 硫氧还蛋白及其相互作用蛋白在结直肠腺瘤中的表达及意义[J]. 肿瘤学杂志, 2021, 27(5):409-411. |
5. |
SHEN L, O'SHEA J M, KAADIGE M R, et al. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP[J]. Proc Natl Acad Sci U S A, 2015, 112(17):5425-5430.
DOI URL |
6. |
HAMILTON J P, POTTER J J, KOGANTI L, et al. Effects of vitamin D3 stimulation of thioredoxin-interacting protein in hepatocellular carcinoma[J]. Hepatol Res, 2014, 44(13):1357-1366.
DOI PMID |
7. |
WEI M, JIAO D, HAN D, et al. Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP[J]. Oncotarget, 2017, 8(3):5323-5338.
DOI PMID |
8. | 杨岚, 代海燕, 鞠传余. 硫氧还蛋白(Trx)对糖尿病视网膜病变模型鼠血清补体Clq肿瘤坏死因子相关蛋白9(CTRP9)表达的影响[J]. 眼科新进展, 2019, 39(3):229-233. |
9. | 李晓敏, 路桂杰, 槐梅, 等. 硫氧还蛋白相互作用蛋白和硫氧还蛋白还原酶1在乳腺浸润性导管癌中的表达及其意义[J]. 中国医刊, 2017, 52(10):99-102. |
10. |
DONG C, ZHANG L, SUN R, et al. Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress[J]. Sci Rep, 2016, 6:36860.
DOI PMID |
11. | 扶涛, 张学云, 骆严. 硫氧还蛋白互作蛋白研究进展[J]. 生命的化学, 2019, 39(3):438-445. |
12. |
QU X, SUN J, ZHANG Y, et al. C-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer[J]. Biochem Biophys Res Commun, 2018, 504(2):415-421.
DOI URL |
13. | 张莉, 朱蕾, 白洁. miR-135a-5p和TXNIP在甲状腺乳头状癌组织中的表达及意义[J]. 中国医师杂志, 2019, 21(8):5. |
14. | 谢鸣, 高磊, 潘铁军. C-MYC和硫氧还蛋白相互作用蛋白在前列腺癌组织的表达及临床意义[J]. 中华实验外科杂志, 2019, 36(2):3. |
15. | 马一嘉, 房辉, 李玉凯, 等. 2型糖尿病患者血清Trx、Txnip与认知功能的相关性[J]. 中国现代医学杂志, 2017, 27(3):59-63. |
16. | 刘玮, 邓征浩, 周建华, 等. FGF-2和TRX在非小细胞肺癌中的表达及临床病理学意义[J]. 中国现代医学杂志, 2010, 20(10):1461-1465. |
17. | 谢光辉. 肺癌患者血清中硫氧还蛋白(TRX)和细胞角蛋白19(CYFRA21-1)的测定及其对肺癌的诊断价值[J]. 延边医学, 2015, 10(15):252-254. |
18. | 肖聪, 张懿敏, 孙圣荣. 硫氧还蛋白互作蛋白在乳腺癌中的研究进展[J]. 医学研究杂志, 2019, 48(11):4. |
[1] | LI Liangshan, ZHAO Hu, WANG Shiwen. Screening potential prognostic biomarkers of colorectal cancer based on weighted gene co-expression network analysis [J]. Laboratory Medicine, 2023, 38(9): 825-832. |
[2] | ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer [J]. Laboratory Medicine, 2023, 38(7): 629-633. |
[3] | JIANG Mengying, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, DU Yan. Clinical role of serum S1P in the early diagnosis of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 307-312. |
[4] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319. |
[5] | ZHOU Furong, LI Yanzhu, LIU Yonggan. Application of lncRNA SNP in colorectal cancer susceptibility prediction and prognosis assessment [J]. Laboratory Medicine, 2023, 38(12): 1206-1210. |
[6] | ZHU Yunjie, MA Zhengyao, SHEN Minna, ZHOU Yan, HUANG Fei, CHEN Xinning, ZHANG Chunyan, WANG Beili, GUO Wei. Establishment and clinical application evaluation of plasma cfDNA determination in colorectal cancer patients [J]. Laboratory Medicine, 2022, 37(6): 561-567. |
[7] | GONG Zhiyun, JIANG Minglei, SHI Weizhong, LU Renquan, GUO Lin. Application value of fecal SDC2 gene methylation determination in the auxiliary diagnosis of colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 325-329. |
[8] | LIU Kai, ZHANG Peiru, XIE Suhong, GUO Lin, LU Renquan. Clinical value of the SorCS1 gene promoter methylation determination in patients with colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 330-335. |
[9] | CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341. |
[10] | XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55. |
[11] | MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59. |
[12] | YANG Chaomei, FENG Jie, LANG Lei, YAN Guangtao. Clinical application value of CTC combined determination with CEA and CA125 in colorectal cancer [J]. Laboratory Medicine, 2021, 36(9): 901-905. |
[13] | FANG Yongyun, LU Daru, SHEN Lisong. Role of ctDNA KRAS mutation determination for therapeutic effectiveness assessment of neo-adjuvant therapy in patients with colorectal cancer [J]. Laboratory Medicine, 2020, 35(9): 875-880. |
[14] | CHEN Xinning, WU Shengchao, GUO Wei, WANG Beili. Plasma ctDNA determination in the diagnosis and treatment of colorectal cancer [J]. Laboratory Medicine, 2020, 35(9): 948-951. |
[15] | LIU Yan, LONG Yin, PAN Weijie, ZHANG Tong, WENG Wenhao, YU Ying. Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer [J]. Laboratory Medicine, 2020, 35(4): 314-317. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||